Dried Blood Spot Sampling in the Monitoring of Anticancer Therapy for Solid Tumors: A Systematic Review.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
received:
06
06
2022
accepted:
04
10
2022
medline:
11
5
2023
pubmed:
8
2
2023
entrez:
7
2
2023
Statut:
ppublish
Résumé
Dried blood spot (DBS) sampling is a convenient alternative to whole-blood sampling for therapeutic drug monitoring (TDM) in clinical practice. The aim of this study was to systematically review studies that have examined and used DBS sampling for the TDM of chemotherapy and targeted therapy agents for the treatment of patients with solid cancers. Using the PRISMA guidelines, a systematic literature search of EMBASE and PUBMED was performed to identify eligible clinical studies that used DBS sampling to monitor chemotherapy or targeted therapy for the treatment of solid cancers. Of the 23 eligible studies, 3 measured concordance between drug concentrations determined by DBS and whole-blood, 7 developed analytical methods of DBS, and 13 performed both. DBS was employed for the TDM of everolimus (3 studies), vemurafenib (2 studies), pazopanib (2 studies), abiraterone (2 studies), mitotane, imatinib, adavosertib, capecitabine, 5-fluorouracil, gemcitabine, cyclophosphamide, ifosfamide, etoposide, irinotecan, docetaxel, gefitinib, palbociclib/ribociclib, and paclitaxel (one study each). The studies included a median of 14 participants (range: 6-34), with 10-50 μL of blood dispensed on DBS cards (20) and Mitra devices (3). Seventeen of the 20 studies that used DBS found no significant impact of the hematocrit on the accuracy and precision of the developed method in the normal hematocrit ranges (eg, 29.0%-59.0%). DBS and plasma or venous concentrations were highly correlated (correlation coefficient, 0.872-0.999) for all drugs, except mitotane, which did not meet a predefined level of significance (r > 0.872; correlation coefficient, r = 0.87, P < 0.0001). DBS provides an alternative sampling strategy for the TDM of many anticancer drugs. Further research is required to establish a standardized approach for sampling and processing DBS samples to allow future implementation.
Sections du résumé
BACKGROUND
Dried blood spot (DBS) sampling is a convenient alternative to whole-blood sampling for therapeutic drug monitoring (TDM) in clinical practice. The aim of this study was to systematically review studies that have examined and used DBS sampling for the TDM of chemotherapy and targeted therapy agents for the treatment of patients with solid cancers.
METHODS
Using the PRISMA guidelines, a systematic literature search of EMBASE and PUBMED was performed to identify eligible clinical studies that used DBS sampling to monitor chemotherapy or targeted therapy for the treatment of solid cancers.
RESULTS
Of the 23 eligible studies, 3 measured concordance between drug concentrations determined by DBS and whole-blood, 7 developed analytical methods of DBS, and 13 performed both. DBS was employed for the TDM of everolimus (3 studies), vemurafenib (2 studies), pazopanib (2 studies), abiraterone (2 studies), mitotane, imatinib, adavosertib, capecitabine, 5-fluorouracil, gemcitabine, cyclophosphamide, ifosfamide, etoposide, irinotecan, docetaxel, gefitinib, palbociclib/ribociclib, and paclitaxel (one study each). The studies included a median of 14 participants (range: 6-34), with 10-50 μL of blood dispensed on DBS cards (20) and Mitra devices (3). Seventeen of the 20 studies that used DBS found no significant impact of the hematocrit on the accuracy and precision of the developed method in the normal hematocrit ranges (eg, 29.0%-59.0%). DBS and plasma or venous concentrations were highly correlated (correlation coefficient, 0.872-0.999) for all drugs, except mitotane, which did not meet a predefined level of significance (r > 0.872; correlation coefficient, r = 0.87, P < 0.0001).
CONCLUSIONS
DBS provides an alternative sampling strategy for the TDM of many anticancer drugs. Further research is required to establish a standardized approach for sampling and processing DBS samples to allow future implementation.
Identifiants
pubmed: 36750444
doi: 10.1097/FTD.0000000000001082
pii: 00007691-202306000-00002
doi:
Substances chimiques
Mitotane
78E4J5IB5J
Antineoplastic Agents
0
Everolimus
9HW64Q8G6G
Vemurafenib
207SMY3FQT
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
293-305Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Kim HY, Martin JH, McLachlan AJ, et al. Precision dosing of targeted anticancer drugs—challenges in the real world. Transl Cancer Res. 2017;6:1500–1511.
Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14:2590–2611.
Menz BD, Stocker SL, Verougstraete N, et al. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. Br J Clin Pharmacol. 2021;87:227–236.
Mizoguchi K, Nakamura Y, Sano K, et al. Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. Cancer Chemother Pharmacol. 2016;78:377–382.
Teng JFT, Mabasa VH, Ensom MHH. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit. 2012;34:85–97.
Moeung S, Chevreau C, Broutin S, et al. Therapeutic drug monitoring of carboplatin in high-dose protocol (TI-CE) for advanced germ cell tumors: pharmacokinetic results of a phase II multicenter study. Clin Cancer Res. 2017;23:7171–7179.
Pignon T, Lacarelle B, Duffaud F, et al. Dosage adjustment of high-dose methotrexate using Bayesian estimation: a comparative study of two different concentrations at the end of 8-h infusions. Ther Drug Monit. 1995;17:471–478.
Bartelink IH, Bredius RG, Ververs TT, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:88–98.
Mauclere-Denost S, Leboulleux S, Borget I, et al. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol. 2012;166:261–268.
Westerdijk K, Desar IM, Steeghs N, et al. Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol. 2020;86:258–273.
Paci A, Veal G, Bardin C, et al. Review of therapeutic drug monitoring of anticancer drugs part 1-cytotoxics. Eur J Cancer. 2014;50:2010–2019.
Lei BUW, Prow TW. A review of microsampling techniques and their social impact. Biomed Microdevices. 2019;21:81.
Wilhelm AJ, den Burger JCG, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin Pharmacokinet. 2014;53:961–973.
Guidance for industry, bioanalytical method validation. Food and drug administration, US department of health and human services web site. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry . Published 2018. Accessed May 8, 2022.
Lange B, Roberts T, Cohn J, et al. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis. 2017;17:693.
Smit PW, Sollis KA, Fiscus S, et al. Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS One. 2014;9:e86461.
Moat SJ, George RS, Carling RS. Use of dried blood spot specimens to monitor patients with inherited metabolic disorders. Int J Neonatal Screen. 2020;6:26.
Moher D, Liberati A, Tetzlaff J, et al., GroupPRISMA Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269.
Singhal P, Shah P, Shah J, et al. Determination of capecitabine-an anticancer drug in dried blood spot by LC-ESI-MS/MS. Int J Pharm Pharm Sci. 2015;7:238–245.
Radovanovic M, Schneider JJ, Shafiei M, et al. Measurement of 5-fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS. J Chromatogr B. 2022;1188:123075.
Kumar DP, Palavan C, Jvln SR. Development and validation of a dried blood spot LC-MS/MS assay to quantify gemcitabine in human whole blood: a comparison with and without cytidine deaminase inhibitor. Int J Pharm Pharm Sci. 2015;7:75–81.
Harahap Y, Gustiyanti N, Sunanto AE, et al. Method development on analysis cyclophosphamide and 4-hydroxycyclophophamide in dried blood spot and its application in breast cancer patients. Int J Appl Pharm. 2020;12:119–125.
Torres LM, Rivera-Espinosa L, Chávez-Pacheco JL, et al. A new method to quantify ifosfamide blood levels using dried blood spots and UPLC-MS/MS in paediatric patients with embryonic solid tumours. PLoS One. 2015;10:e0143421.
Režonja Kukec R, Grabnar I, Mrhar A, et al. A simple dried blood spot method for clinical pharmacological analyses of etoposide in cancer patients using liquid chromatography and fluorescence detection. Clinica Chim Acta. 2016;452:99–105.
Hahn RZ, Arnhold PC, Andriguetti NB, et al. Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection. J Pharm Biomed Anal. 2018;150:51–58.
Raymundo S, Muller VV, Andriguetti NB, et al. Determination of docetaxel in dried blood spots by LC-MS/MS: method development, validation and clinical application. J Pharm Biomed Anal. 2018;157:84–91.
Andriguetti NB, Hahn RZ, Lizot LF, et al. Analytical and clinical validation of a dried blood spot assay for the determination of paclitaxel using high-performance liquid chromatography-tandem mass spectrometry. Clin Biochem. 2018;54:123–130.
Friedl B, Kurlbaum M, Kroiss M, et al. A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring. Anal Bioanal Chem. 2019;411:3951–3962.
Xu Y, Fang W, Zeng W, et al. Evaluation of dried blood spot (DBS) technology versus plasma analysis for the determination of MK-1775 by HILIC-MS/MS in support of clinical studies. Anal Bioanal Chem. 2012;404:3037–3048.
Nijenhuis CM, Rosing H, Schellens JH, et al. Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS. Bioanalysis. 2014;6:3215–3224.
Nijenhuis CM, Huitema AD, Marchetti S, et al. The use of dried blood spots for pharmacokinetic monitoring of vemurafenib treatment in melanoma patients. J Clin Pharmacol. 2016;56:1307–1312.
Verheijen RB, Bins S, Thijssen B, et al. Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS. Bioanalysis. 2016;8:123–134.
de Wit D, den Hartigh J, Gelderblom H, et al. Dried blood spot analysis for therapeutic drug monitoring of pazopanib. J Clin Pharmacol. 2015;55:1344–1350.
Knapen LM, Beer Yd, Brüggemann RJM, et al. Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting. J Pharm Biomed Anal. 2018;149:106–113.
Willemsen AECAB, Knapen LM, de Beer YM, et al. Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer. Eur J Clin Pharmacol. 2018;74:465–471.
Verheijen RB, Thijssen B, Atrafi F, et al. Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling. J Chromatogr B. 2019;1104:234–239.
Irie K, Shobu S, Hiratsuji S, et al. Development and validation of a method for gefitinib quantification in dried blood spots using liquid chromatography-tandem mass spectrometry: application to finger-prick clinical blood samples of patients with non-small cell lung cancer. J Chromatogr B. 2018;1087-1088:1–5.
Iacuzzi V, Posocco B, Zanchetta M, et al. Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients. PLoS One. 2019;14:e0225225.
Bhatnagar A, McKay MJ, Thaysen-Andersen M, et al. Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients. J Chromatogr B. 2019;1126-1127:121741.
Dillenburg Weiss TL, Gössling G, Venzon Antunes M, et al. Evaluation of dried blood spots as an alternative matrix for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in prostate cancer patients. J Pharm Biomed Anal. 2021;195:113861.
Poetto AS, Posocco B, Gagno S, et al. A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer. J Chromatogr B. 2021;1185:122985.
Krens SD, McLeod HL, Hertz DL. Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. Pharmacogenomics. 2013;14:555–574.
Joerger M, Kraff S, Huitema ADR, et al. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet. 2012;51:607–617.
Moffat AC, Osselton MD, Widdop B, et al. Clarke's analysis of drugs and poisons. Vol 3. London: Pharmaceutical press; 2011. https://www.worldcat.org/title/clarkes-analysis-of-drugs-and-poisons-in-pharmaceuticals-body-fluids-and-postmortem-material/oclc/733491270 . Accessed May 8, 2022. Published.
Li W, Tse FLS. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed Chromatogr. 2010;24:49–65.
Iacuzzi V, Posocco B, Zanchetta M, et al. Dried blood spot technique applied in therapeutic drug monitoring of anticancer drugs: a review on conversion methods to correlate plasma and dried blood spot concentrations. Pharm Res. 2021;38:759–778.
Denniff P, Spooner N. The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs. Bioanalysis. 2010;2:1385–1395.
Capiau S, Veenhof H, Koster RA, et al. Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring. Ther Drug Monit. 2019;41:409–430.
Cobb Z, de Vries R, Spooner N, et al. In-depth study of homogeneity in DBS using two different techniques: results from the EBF DBS microsampling consortium. Bioanalysis. 2013;5:2161–2169.
Denniff P, Spooner N. Volumetric absorptive microsampling: a dried sample collection technique for quantitative bioanalysis. Anal Chem. 2014;86:8489–8495.
De Kesel PMM, Lambert WE, Stove CP. Does volumetric absorptive microsampling eliminate the hematocrit bias for caffeine and paraxanthine in dried blood samples? A comparative study. Analytica Chim Acta. 2015;881:65–73.
Cheung CY, van der Heijden J, Hoogtanders K, et al. Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl Int. 2008;21:140–145.
Kromdijk W, Mulder JW, Smit PM, et al. Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof-of-concept study. Antivir Ther. 2012;18:821–825.